Gapwaves begins waveguide antenna production for Valeo
The production kick-off took place last week at Gapwaves' facility in Gothenburg, Sweden, with the first series delivery to Valeo completed on 1 July.
The Gothenburg facility, inaugurated last November, is pivotal for developing, testing, and validating scalable production processes before transferring them to global production partners.
Following the initial production phase in Gothenburg, Gapwaves will transfer the production to Frencken Group in China for full-scale, automated series production under Gapwaves' supervision.
Valeo's new vehicle radar, incorporating Gapwaves' antennas, is set to enhance ADAS functionalities, such as blind spot warning and cross-traffic alert systems.
Gapwaves said, its partnership with Valeo has resulted in a 'cost-effective radar' with substantially improved performance.
Gapwaves CEO Jonas Ehinger said: "This is a very important milestone for Gapwaves. Our new pilot line in Gothenburg has been crucial for us to maintain such short lead times from the development of the new antenna all the way to production, while maintaining the highest quality, and demonstrating that we meet the requirements according to the high standards of the automotive industry.
'Over the past year, Gapwaves has taken many important steps in our commercialisation journey, and having production up and running for Valeo, a world leader in ADAS systems, is a strong testament to Gapwaves positioning."
Gapwaves' multi-layer waveguide technology offers high-end performance at reduced costs.
Gapwaves is set to produce approximately 435,000 antennas this year and an estimated 4.5 million in 2026, an increase from the 60,000 produced between 2011 and 2023.
"Gapwaves begins waveguide antenna production for Valeo" was originally created and published by Just Auto, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
9 minutes ago
- Bloomberg
Trade Deal Leaves Vietnam With Questions and One Big Challenge
With the dust far from having settled on this week's US-Vietnam trade agreement, one thing is clear: companies operating in what's become one of the most vibrant Asian economies are on notice to move up the value chain. A key element of the deal first unveiled by US President Donald Trump is a differentiated tariff setting, with a 20% American surtax on Vietnamese-produced goods and a 40% levy on those trans-shipped from elsewhere through Vietnam. That's largely aimed at China, which produces many of the inputs companies operating in its southern neighbor use for assembling their products.
Associated Press
33 minutes ago
- Associated Press
Leading Independent Proxy Advisory Firm ISS Joins Glass Lewis in Recommending Shareholders Vote to Keep the Current SINOVAC Board in Place
BEIJING--(BUSINESS WIRE)--Jul 3, 2025-- The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (' SINOVAC ' or the ' Company '), a leading provider of biopharmaceutical products in China, today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. ('ISS') has joined Glass, Lewis & Co. ('Glass Lewis') in recommending that SINOVAC shareholders vote to KEEP the current SINOVAC Board in place by voting the WHITE proxy card 'AGAINST' the election of the Reconstituted Imposter Former Board Slate at the upcoming Special Meeting of Shareholders (the 'Special Meeting'). The SINOVAC Board issued the following statement in response to ISS' recommendation: 'We are thrilled that independent proxy advisors ISS and Glass Lewis recommended shareholders vote to KEEP SINOVAC's current Board in place and OPPOSE the Reconstituted Imposter Former Board Slate. In making their recommendations, ISS and Glass Lewis both recognized the swift actions the current SINOVAC Board has taken to restore fairness and deliver value to SINOVAC's rightful shareholders, and they have criticized the Imposter Former Board's abject governance failures that robbed value from SINOVAC shareholders during its seven-year 'de facto' tenure. 'The facts speak for themselves: over the past four months, the current SINOVAC Board has demonstrated its commitment to righting the wrongs of the Imposter Former Board. The current Board has declared a US$55.00 per common share special cash dividend and has continued to lay the groundwork for additional distributions, is working with NASDAQ to resume trading, and is launching a formal exploration of a future listing on the Stock Exchange of Hong Kong to promote liquidity and support shareholder value creation. 'In contrast, the Imposter Former Board, in close coordination with SAIF, Advantech/Prime Success ('Advantech/Prime') and Vivo Capital (together, 'the Dissenting Investor Group'), continue to attempt to derail our progress through misleading rhetoric, baseless claims and frivolous legal actions. Their self-serving objective is clear: regain control of SINOVAC and deprive common shareholders of their rightful dividend payments. 'We urge shareholders to follow the recommendations of both leading independent proxy advisory firms by voting AGAINST the election of the Reconstituted Imposter Former Board on the WHITE proxy card.' Highlights from the ISS Report include 1 (emphasis added): SUPERIORITY OF THE CURRENT BOARD DIVIDEND PAYMENTS POISON PILL AND NASDAQ TRADING HALT IMPOSTER FORMER BOARD'S SELF-DEALING At the Special Meeting, shareholders will have the chance to send a clear message to the Dissenting Investor Group: SINOVAC will no longer be held captive to their self-dealing. SINOVAC's Board urges shareholders to protect their investment and the future of their Company by voting the WHITE proxy card today 'AGAINST' Proposals 1 and 2 at the Special Meeting. For more details on the misdeeds and shareholder harm caused by the Imposter Former Board and Dissenting Investor Group, visit our website Your Vote is Important Your vote on or before July 8 will be about the future of SINOVAC, your receipt of your make-whole dividend payments in the near-term, and the long-term value of your investment. We urge you to keep SINOVAC's Board in place and vote on the WHITE proxy card ' AGAINST ' Proposal 1 to remove the current Board and ' AGAINST ' Proposal 2 to appoint the Reconstituted Imposter Former Board Slate. Your vote is critical to ensuring that SINOVAC remains on the path to stability, growth, and value creation for all shareholders. DISCARD any items you received asking you to vote for the Reconstituted Imposter Former Board Slate. If you have already voted for the Reconstituted Imposter Former Board Slate, you can subsequently revoke it by using the WHITE proxy card or WHITE voting instruction form to vote. Only your latest-dated vote will count! The Special Meeting of Shareholders will be held on Wednesday, July 9, 2025, at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025, at 8:00 p.m. Atlantic Standard Time). Valid shareholders of record as of the close of business on May 19, 2025, are entitled to vote at the meeting. If you have any questions about locating your control number or voting your shares, please contact our proxy solicitor, Georgeson LLC, toll free at (844) 568-1506 in the U.S and (646) 543-1968 outside the U.S. or via email at[email protected]. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under 'Category 1 Preventative Biological Products' and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Important Additional Information and Where to Find It In connection with SINOVAC's Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission ('SEC') and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC's website, or from SINOVAC at its website: You may also obtain copies of SINOVAC's definitive proxy statement and other documents, free of charge, by contacting SINOVAC's Investor Relations Department at [email protected]. Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'potential,' 'continue,' 'is/are likely to' or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law. View source version on CONTACT: Investor and Media FGS Global [email protected] KEYWORD: CHINA UNITED STATES NORTH AMERICA ASIA PACIFIC INDUSTRY KEYWORD: INFECTIOUS DISEASES BIOTECHNOLOGY PHARMACEUTICAL HEALTH SOURCE: The Board of Directors of Sinovac Biotech Ltd. Copyright Business Wire 2025. PUB: 07/03/2025 07:34 PM/DISC: 07/03/2025 07:34 PM
Yahoo
an hour ago
- Yahoo
US judge says China's Huawei Technologies must face criminal case for racketeering and other charges
BANGKOK (AP) — A U.S. judge has ruled that China's Huawei Technologies, a leading telecoms equipment company, must face criminal charges in a wide reaching case alleging it stole technology and engaged in racketeering, wire and bank fraud and other crimes. U.S. District Judge Ann Donnelly on Tuesday rejected Huawei's request to dismiss the allegations in a 16-count federal indictment against the company, saying in a 52-page ruling that its arguments were premature. The company did not immediately respond to a request for comment. The U.S. accuses Huawei and some of its subsidiaries of plotting to steal U.S. trade secrets, installing surveillance equipment that enabled Iran to spy on protesters during 2009 anti-government demonstrations in Iran, and of doing business in North Korea despite U.S. sanctions there. During President Donald Trump's first term in office, his administration raised national security concerns and began lobbying Western allies against including Huawei in their wireless, high-speed networks. In its January 2019 indictment, the Justice Department accused Huawei of using a Hong Kong shell company called Skycom to sell equipment to Iran in violation of U.S. sanctions and charged its chief financial officer, Meng Wanzhou, with fraud by misleading the HSBC bank about the company's business dealings in Iran. Meng, the daughter of Huawei's founder, was arrested in Canada in late 2018 on a U.S. extradition request but released in September 2021 in a high-stakes prisoner swap that freed two Canadians held by China and allowed her to return home. Chinese officials have accused the U.S. government of 'economic bullying' and of improperly using national security as a pretext for 'oppressing Chinese companies.' In their motion to dismiss the broad criminal case, among other arguments Huawei's lawyers contended that the U.S. allegations were too vague and some were 'impermissibly extraterritorial," and do not involve domestic wire and bank fraud. The biggest maker of network gear, Huawei struggled to hold onto its market share under sanctions that have blocked its access to most U.S. processor chips and other technology. The limits led it to ramp up its own development of computer chips and other advanced technologies. The company also shifted its focus to the Chinese market and to network technology for hospitals, factories and other industrial customers and other products that would not be affected by U.S. sanctions.
